113th Annual General Meeting of Shareholders

1. Business Report, Consolidated Financial Statements and Non-consolidated Financial Statements for the 113th Business Term (April 1, 2024 to March 31, 2025)
2. The Audit Reports by the Accounting Auditors and the Board of Corporate Auditors on the consolidated Financial Statements for the 113th Business Term (April 1, 2024 to March 31, 2025)

We received questions regarding the following subjects from shareholders in advance and answered each question on the Meeting.

1. Measures to raise stock price in the future.
2. On whether outside directors with short tenures can play an adequate role in the supervision of management and in important decision-making situations.
3. Positioning of the U.S. Business in the New Medium-Term Management Plan.
4. Plan for development and introduction of products targeting the retinal area.

We received questions and comments regarding the following subjects from 2 shareholders attended and responded in kind.

1. Request of message from Mr. Akira Kurokawa, who will be resigned at this annual general meeting.
2. Future prospects in an environment in which NHI price and medical fee are unlikely to raise.
3. Request to management to strengthen our human resources and organization.